Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors

Xiong, Bin; Fu, Baoyue; Wu, Yafang; Gao, Fei; Hou, Changlong

doi:10.1007/s00432-023-05051-z

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia is a major actor in the natural history of HCC, as highlighted by Liu et al in a recent meta-analysis on 8959 HCC patients in which 42% of the whole cohort was sarcopenic [8]. As clearly discussed above, sarcopenia has a negative impact in each stage of the disease and implies worse prognosis in terms of the therapeutic response, OS [9,15,24,[60][61][62]70,71], surgical complications [10,56,57] and HCC recurrence [56].…”

Section: Discussionmentioning

confidence: 95%

“…Xiong and colleagues [70] recently conducted a study exploring the prognostic relevance of sarcopenia in patients undergoing immune checkpoint inhibitor therapy. Utilizing CT scans, sarcopenia was assessed by computing various parameters such as the SMI, visceral adipose tissue index, subcutaneous adipose tissue index (SATI) and total adipose tissue index.…”

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 99%

“…Utilizing CT scans, sarcopenia was assessed by computing various parameters such as the SMI, visceral adipose tissue index, subcutaneous adipose tissue index (SATI) and total adipose tissue index. A multivariate analysis demonstrated that both the SATI (HR 0.251; 95% CI 0.109-0.577; p = 0.001) and the presence of sarcopenia (sarcopenia vs. no sarcopenia; HR 2.171; 95% CI 1.100-4.284; p = 0.026) independently served as prognostic indicators for the OS [70].…”

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Esposto,

Borriello,

Galasso

et al. 2024

Diagnostics

View full text Add to dashboard Cite

The condition of sarcopenia, defined as a progressive loss of musculoskeletal mass and muscular strength, is very common in patients with hepatocellular carcinoma (HCC) and presents a remarkable association with its prognosis. Thus, the early identification of sarcopenic patients represents one of the potential new approaches in the global assessment of HCC, and there is increasing interest regarding the potential therapeutic implications of this condition. The gold standard for the quantification of muscle mass is magnetic resonance imaging (MRI) or computed tomography (CT), but these techniques are not always feasible because of the high-cost equipment needed. A new possibility in sarcopenia identification could be muscle ultrasound examination. The measurement of specific parameters such as the muscle thickness, muscular fascicles length or pennation angle has shown a good correlation with CT or MRI values and a good diagnostic accuracy in the detection of sarcopenia. Recently, these results were also confirmed specifically in patients with chronic liver disease. This review summarizes the role of imaging for the diagnosis of sarcopenia in patients with HCC, focusing on the advantages and disadvantages of the diagnostic techniques currently validated for this aim and the future perspectives for the identification of this condition.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 99%

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Esposto,

Borriello,

Galasso

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy

Zhang,

Li,

Wang

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients

Ji,

Li,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionChronic viral infection may lead to an immunosuppressive microenvironment, whereas the association between virus-related indicators and treatment response in hepatocellular carcinoma(HCC) patients undergoing immune checkpoint inhibitors(ICIs) therapy remains a topic of debate. We aim to investigate the influence of hepatitis virus on the ICI efficiency in HCC patients through a meta-analysis.MethodsWe searched PubMed, Cochrane Library, Embase, and Web of Science until 14 July 2024 to identify cohort studies involving ICIs treatments in HCC patients. We extracted data from the literature related to hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, baseline HBV load, and antiviral therapy. Overall survival (OS) and progression-free survival (PFS) were considered as the primary endpoints, while objective response rate (ORR) was regarded as a secondary endpoint.ResultsWe included 55 cohort studies published between 2019 and 2024, involving a patient population of 7180 individuals. Summarized hazard ratio (HR) comparing HBV infection with non-HBV infection in the context of ICIs therapy revealed no significant association between HBV infection and either mortality risk or progression risk with the pooled HR for OS of 1.04(95%CI: 0.93-1.16, P=0.483) and the pooled HR for PFS of 1.07(95%CI:0.96-1.20, P=0.342). HBV infected patients with HCC may have better tumor response than non-HBV infected patients receiving ICIs with the combined relative risk(RR) for ORR was 1.94 (95%CI: 1.12-3.38, P=0.002). High baseline HBV load is associated with poor survival outcomes in patients with HCC who receive ICIs with the pooled HR for OS was 1.74 (95%CI: 1.27-2.37, P=0.001), thereby antiviral therapy has the potential to significantly enhance prognostic outcomes with the pooled HR for OS was 0.24 (95% CI: 0.14-0.42 P<0.001) and the pooled HR for PFS was 0.54 (95% CI: 0.33-0.89 P=0.014).ConclusionIn individuals with HCC who received ICIs, there was no notable link found between HBV or HCV infection and prognosis. However, HBV infection showed a connection with improved tumor response. A higher initial HBV load is linked to worse survival results in HCC patients undergoing ICIs treatment and antiviral therapy can significantly improve its prognosis.

show abstract

Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors

Cited by 5 publications

References 32 publications

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy

The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients

Contact Info

Product

Resources

About